328 results on '"de Andrade, Joao"'
Search Results
52. Solid Waste Management as an instrument of sustainability in protestant denominations
53. SCREENING FOR PULMONARY HYPERTENSION IN PATIENTS WITH INTERSTITIAL LUNG DISEASE: RECOMMENDATIONS FROM A DELPHI CONSENSUS PANEL
54. Turbulent Cerebrospinal Fluid Flow in Enlarging Terminal Myelocystocele
55. Soluble P-Selectin and the Risk of Primary Graft Dysfunction After Lung Transplantation
56. Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.
57. Solid Waste Management as an instrument of sustainability in protestant denominations
58. New Insights into the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis
59. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
60. The senescence-associated matricellular protein CCN1 in plasma of human subjects with idiopathic pulmonary fibrosis
61. Citrullinated vimentin mediates development and progression of lung fibrosis
62. Classifier Ensemble Based on Computed Tomography Attenuation Patterns for Computer-Aided Detection System
63. Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib
64. Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial
65. A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
66. Preoperative Evaluation of Patients With Interstitial Lung Disease
67. The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods
68. Integrative clustering analysis to discover novel IPF disease subtypes in the IPF-PRO Registry
69. Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
70. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis
71. Assessment of Viral RNA in Idiopathic Pulmonary Fibrosis Using RNA-seq
72. BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
73. Association of Protein C and Type 1 Plasminogen Activator Inhibitor with Primary Graft Dysfunction
74. Split-plot design optimization for trace determination of lead by anodic stripping voltammetry in a homogeneous ternary solvent system
75. Patient Registries in Idiopathic Pulmonary Fibrosis.
76. Direct voltammetric determination of Mo(VI) in plants: the need for a multivariate study of interferences
77. The Lung in Systemic Lupus Erythematosus
78. Preoperative Evaluation of Patients With Interstitial Lung Disease
79. Assessment of Viral RNA in Idiopathic Pulmonary Fibrosis Using RNA-seq
80. Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients
81. Patient Registries in Idiopathic Pulmonary Fibrosis
82. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis
83. Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis
84. Predicting Outcome in Idiopathic Pulmonary Fibrosis: Addition of Fibrotic Score at Thin-Section CT of the Chest to Gender, Age, and Physiology Score Improves the Prediction Model
85. Determination of organic matter in soils using radial basis function networks and near infrared spectroscopy
86. Idiopathic Pulmonary Fibrosis: Exploring the Clinical and Economic Implications of the Evolving Treatment Landscape.
87. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection
88. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence
89. Multivariate calibration applied to a highly interfering chemical system: The simultaneous spectrophotometric determination of aluminium and iron in plants using xylenol orange and partial least-squares regression
90. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence
91. CHARACTERISTICS OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) IN THE US: DATA FROM THE IPF-PRO REGISTRY
92. Baseline characteristics of 1461 participants in the Pulmonary Fibrosis Foundation Patient Registry
93. Predictors of death or transplant in patients with idiopathic pulmonary fibrosis in the IPF-PRO Registry
94. Abstract TP327: Predictors of Spontaneous Hemorrhagic Transformation in Patients Not Treated With Recanalization Therapies
95. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
96. Clustering of regional HDI data using Self-Organizing Maps
97. Effect of an Online Educational Intervention in the Knowledge of Diagnosis and Management of Idiopathic Pulmonary Fibrosis Among Pulmonologists
98. Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis
99. Patient journey to diagnosis of idiopathic pulmonary fibrosis (IPF) in the US
100. Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.